Glucagon News and Research

RSS

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

Study links semaglutide to reduced opioid overdose risk in patients with OUD and diabetes

Since being deemed a public health emergency in 2017, opioids are responsible for 72% of drug overdose deaths in the United States, according to the National Center for Drug Abuse Statistics.

25 Sep 2024

Semaglutide shows promise in treating chronic skin condition in obese patients

A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.

24 Sep 2024

New guidelines for cardiovascular management in noncardiac surgery released

The 2024 guideline for cardiovascular management of adults undergoing noncardiac surgery reflects a decade of updates and new evidence since the guideline's last release in 2014.

24 Sep 2024

Liraglutide activates key brain circuits to trigger weight loss in obesity

Researchers uncover how liraglutide targets specific brain regions to suppress appetite and promote significant weight loss through GLP-1 receptor activation.

23 Sep 2024

Yoyo dieting alters gut health, driving weight regain and inflammation

Researchers from Deakin University reveal how yoyo dieting disrupts gut health, leading to weight regain and obesity-related complications. The study highlights the roles of gut microbiota, hormones, and inflammation in the weight cycling process.

23 Sep 2024

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Researchers compare the weight loss efficacy of injectable liraglutide and semaglutide.

17 Sep 2024

Real-world data reveals factors associated with long-term weight loss in obesity

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or obesity. The study was published in JAMA Network Open.

14 Sep 2024

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the need for additional studies.

13 Sep 2024

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety signals, offering insights into potential obesity treatments.

12 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Women experience greater weight loss with tirzepatide compared to men

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

11 Sep 2024

Obesity medication liraglutide safe and effective in children under 12, research finds

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

10 Sep 2024

Once-a-day oral weight loss drug shows promising results in reducing body weight

Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.

10 Sep 2024

GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

9 Sep 2024

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

9 Sep 2024

Study shows beta cells can function independently for glycemic control

Our glycemic balance is based on the ability of the pancreatic beta cells to detect glucose and secrete insulin to maintain our blood sugar levels. If these cells malfunction, the balance is broken, and diabetes develops.

3 Sep 2024

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

Is semaglutide use during breastfeeding safe?

Researchers found no detectable levels of semaglutide in breast milk, suggesting minimal risk to breastfed infants, but highlighted the need for monitoring maternal nutrition and milk production.

2 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Glucagon News and Research

New pipeline of drug candidates offers hope for effective MASLD treatments

Study links semaglutide to reduced opioid overdose risk in patients with OUD and diabetes

Semaglutide shows promise in treating chronic skin condition in obese patients

New guidelines for cardiovascular management in noncardiac surgery released

Liraglutide activates key brain circuits to trigger weight loss in obesity

Yoyo dieting alters gut health, driving weight regain and inflammation

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Real-world data reveals factors associated with long-term weight loss in obesity

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

Women experience greater weight loss with tirzepatide compared to men

Obesity medication liraglutide safe and effective in children under 12, research finds

Once-a-day oral weight loss drug shows promising results in reducing body weight

GLP-1 receptor agonists show promise in treating substance use disorders

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

Study shows beta cells can function independently for glycemic control

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Is semaglutide use during breastfeeding safe?

ESC consensus statement highlights obesity's impact on cardiovascular disease

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News